Pancreatic Ductal Adenocarcinoma

Debate: Molecular Therapies in Pancreatic Ductal Adenocarcinoma: NGS for All or None - CON by Thierry Conroy @ #WCGIC2023 👉fair word of caution on broad NGS testing > we need to make more progress 👇Interesting observation, not to be forgotten in the clinic @myESMO @OncoAlert… https://t.co/i7lHf9Yk2B (@ArndtVogel)

Debate: Molecular Therapies in Pancreatic Ductal Adenocarcinoma: NGS for All or None - CON by Thierry Conroy @ #WCGIC2023 👉fair word of caution on broad NGS testing > we need to make more progress 👇Interesting observation, not to forget in the clinic @myESMO @OncoAlert @WCGIC… https://t.co/xiKJHMRzse (@ArndtVogel)

Molecular Therapies in Pancreatic Ductal Adenocarcinoma: NGS for All or None - PRO by Philip Phillips at #WCGIC2023 👉search for the rare 🎯💊 in #PancreaticCancer @myesmo @OncoAlert @WCGIC (@ArndtVogel)

Textbook outcomes among patients undergoing curative resection of pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy @JipingWangMD @raaudisio @PompiliuPiso @mirandalammd @JamesClearyMD @JoeChangMD @leo_jyz Clinical Surgical Oncology paper: https://t.co/5KorXtIent (@OncologyAdvance)

New Published Article Sharing 👏Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma 👉https://t.co/yWGA8UdHFp #Pancreaticcancer #tumorresistance #microenvironment #immunecheckpointinhibitors @rachnatshroff @HCCvPDAC @MadameSurgeon @claus_jorgensen (@cdrjournal)

In @CCR_AACR from @GarridoLagunaMD @cancerassassin1 @rachnatshroff @PeterHoseinMD et al: Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC https://t.co/olGLjUk1er (@Aiims1742)

Translational advances in pancreatic ductal adenocarcinoma therapy ⁦@NatureCancer⁩ ⁦@Aiims1742⁩ ⁦@AndrewMWaters⁩ ⁦@krushnacpatra⁩ ⁦@DavendraSohal⁩ ⁦@SWOG⁩ https://t.co/acZT1kAN1C (@SyedAAhmad5)

✨DON’T MISS THIS @NatureCancer REVIEW ARTICLE – “Translational advances in pancreatic ductal adenocarcinoma therapy”by #AbdelNasserHosein #StephanieKDougan #AndrewAguirre @Aiims1742 Find it here👇 https://t.co/zzA3d2HVlC https://t.co/XbWEOseuDG (@NatureCancer)

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma https://t.co/ah9BenEKMS (@MLPOncoData)

Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma https://t.co/iem7C2ydKC (@MLPOncoData)

HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma. https://t.co/KW7W8bEHiW By @OncotargetJrnl - IF 2022-2023 - 0.966 (via @QxMD) “Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma… https://t.co/RZKJ3mNE82 (@vitor__moutinho)

CD40-Directed SEA-CD40 Combo Denotes Antitumor Activity in Pancreatic Ductal Adenocarcinoma https://t.co/DJIbU1gt5y via @onclive #GI23 (@DrBonillaOnc)

New #JITC article: Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma https://t.co/OkuWBuwrwF @lawfong @AACRPres @coussens_lisa (@jitcancer)

@JCOPO_ASCO Impact of #PrecisionOncology in #PDAC #pancreatic cancers! "Response to Seribantumab, anti-HER3 #monoclonalAb in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an NRG1 Fusion" https://t.co/hBFyAJuwfz @OncoAlert @MPishvaian @pashtoonkasi (@ADesaiMD)

Exceptional Response to Erdafitinib in #FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma: https://t.co/pFXGwH2DFc #PancSM #PancreaticCancer #MolecularInsights @jgong15 @DrArsenOsipov @DrHendifar (@JNCCN)

🔥FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope? 🔥 https://t.co/Pjgui96OTQ ✅4 intersting cases responding to FGFRi 👉all KRAS WT with comparable long survival 🧐non-typical fusion partners 🎯Early NGS in KRAS WT #PDAC❗️ @myESMO @OncoAlert (@ArndtVogel)

I go with a pancreatic ductal adenocarcinoma, 1st metastazing in lung (CDX2 weak/mod) and 2nd in large bowel (negative with positive control in benign crypts) (@nucleololailo)

Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma | Nature Communications https://t.co/Xj4Ot866tX (@jonathanloree)

Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma | Nature Communications https://t.co/TJi8X760Nm (@weldeiry)

METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma | Nature Cancer https://t.co/rl5p6YPzln (@weldeiry)

Congrats to the team on publication of this project in @CCR_AACR: Multi-omic characterization of pancreatic ductal adenocarcinoma relates CXCR4 mRNA expression levels to potential clinical targets. https://t.co/no5Z5FyWCh @carisls Precision Oncology Alliance GI Cancer consortium (@cancerassassin1)

Start your morning at #ASCO22 with some 🔥 research by @cancerassassin1. Coming up in 30 mins: The tumor microenvironment and immune infiltration landscape of KRAS mutant pancreatic ductal adenocarcinomas compared to colorectal adenocarcinomas. (@ACS_Research)

IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway [2021. @MoffittNews. @MDAndersonNews. @WakeForest. @WakeCancer. Tianjin Medical Univ General Hospital] https://t.co/BfGHDDtIPS (@WaltherCancerIn)

IRAK4 signaling drives resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma - Gastroenterology https://t.co/26ohMf9l6Q (@weldeiry)

Adagrasib monotherapy demonstrated encouraging clinical activity in patients with previously treated pancreatic ductal adenocarcinoma and other non–colorectal gastrointestinal tumors that harbor KRAS G12C mutations. @GIcancerDoc @MayoClinic @ASCO #GI22 https://t.co/r17E1CxGep (@OncLive)

As a corollary, a KRAS + RNF43 + TP53 mutant colloid carcinoma (#PancreaticCancer / #PancreaticDuctalAdenocarcinoma) arising in an #IPMN. #PancreaticCysts #EarlyDetection (@PancPathologist)

New preprint from one of the currently funded @SU2C @lustgartenfdn #PancreaticCancer Collective teams at @NKI_nl & @TU_Muenchen Combined SHP2 and ERK inhibition for the treatment of KRAS-driven Pancreatic Ductal Adenocarcinoma https://t.co/FGqtMROD5R (@Aiims1742)

the trial referenced... AMPLIFY-201 Study of ELI-002 in Subjects With #KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) & Other Solid Tumor Phase 1/2 159 patients 11 US locations including...University of Iowa #colorectal cancer #CRCSM @kRasKickers https://t.co/nzEAjedSSV (@fireflyann)

#TumorBoardTuesday #PrecisionMedicine KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities https://t.co/hLvCaJHmlS (@ShimaghavimiMD)

📑The #authors of this study tested GATA6 immunohistochemistry IHC as a putative #biomarker in advanced pancreatic ductal #adenocarcinoma ‼️ The results showed that low GATA6 IHC expression was associated with shorter OS🤔💡 https://t.co/bFor0ei507 (@Dr_Ivanoncologo)

Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma https://t.co/1kXpFV2OK9 via @MDPIOpenAccess @AKE_Path @allantsung @LAbushahin (@AshishManne)

Dr Eileen O'Reilly @sloan_kettering highlights that kras wildtype pancreatic ductal adenocarcinoma is a real phenomenon (not just an artifact of quality control and DNA extraction) with potentially actionable targets #pancsm #GDUGI2021 (@marklewismd)

Beautifully written review in @Gut_BMJ on exploiting DNA damage repair defects in treatment of pancreatic ductal adenocarcinoma #pancsm (Also: I was today years old when I learned that PALB2 stands for Partner And Localizer of BRCA2) https://t.co/4o2Bft4Mmn (@marklewismd)

S100P in the diagnosis of pancreatic ductal adenocarcinoma as well 🤓 https://t.co/qF5a62sUHx (@liverwei)

"These data show promising response rates w/ impressive durability across several KRAS variants following treatment," @the_danielahn "We believe these clinical benefits can be extended to [pancreatic ductal adenocarcinoma], as approximately 95% have a #KRAS mutation..." #pancsm (@fireflyann)

Novel ALK Fusion, PPFIBP1-ALK , in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib https://t.co/V6Q2fBUARY (@VivekSubbiah)